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Background: To assess the activity and toxicity of 2-chlorodeoxyadenosine (cladribine, CDA) given
by subcutaneous bolus injections to patients with hairy cell leukemia (HCL).
Patients and methods: Sixty-two eligible patients with classic or prolymphocytic HCL (33 non-
pretreated patients, 15 patients with relapse after previous treatment, and 14 patients with progressive
disease during a treatment other than CDA) were treated with CDA 0.14 mg/kg/day by subcutaneous
bolus injections for five consecutive days. Response status was repeatedly assessed according to the
Consensus Resolution criteria.
Results: Complete and partial remissions were seen in 47 (76%) and 13 (21%) patients, respectively,
for a response rate of 97%. All responses were achieved with a single treatment course. Most responses
occurred early (i.e. within 10 weeks) after start of CDA therapy, but response quality improved during
weeks and even months after treatment completion. The median time to treatment failure for all patients
was 38 months. Leukopenia was the main toxicity. Granulocyte nadir (median 0.2 × 109/l) was strongly
associated with the incidence of infections (P = 0.0013). Non-specific lymphopenia occurred early
after CDA treatment, and normal lymphocytes recovered slowly over several months. No significant
associations were found between infections and nadir count of lymphocytes or any lymphocyte sub-
population. No opportunistic infections were observed.
Conclusions: One course of CDA given by subcutaneous bolus injections is very effective in HCL.
The subcutaneous administration is more convenient for patients and care providers, and has a similar
toxicity profile to continuous intravenous infusion. The subcutaneous administration of CDA is a sub-
stantial improvement and should be offered to every patient with HCL requiring treatment with CDA.
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Introduction
Hairy cell leukemia (HCL) is a chronic lymphoproliferative
disease of B-cell lineage with an indolent, but progressive
course [1, 2]. The disease is characterized by the presence of
abnormal mononuclear cells with irregular cytoplasmic pro-
jections. These ‘hairy cells’ contain cytoplasmic vesicles with
positive cytochemical staining for tartrate-resistant acid phos-
phatase (TRAP) in more than 95% of all cases [3], and they
typically express a panel of mature B-cell surface markers [4]
including CD19, CD20 and CD22, as well as lineage-non-
specific markers such as CD11c, CD25 and CD103. In spite of
the characteristics observed in classic HCL, the disease may
present with a wide range of features which overlap with other
hematological malignancies [5, 6]. Combination of morpho-
logical and clinical criteria, cytochemistry and immunopheno-
type analysis is therefore required for accurate diagnosis of
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HCL [7]. A prolymphocytic variant of HCL has been described
which may be a disease intermediate between HCL and B-cell
prolymphocytic leukemia [8–11].
HCL is characterized by infiltration of bone marrow and
spleen, but other organs may be affected as well. Common
presenting symptoms are splenomegaly, peripheral cytopenia,
a variable proportion of circulating tumor cells, frequent infec-
tions due to impaired immunity, bleeding tendency, and fatigue.
Splenectomy, aimed at improving cytopenias secondary to
hypersplenism, was the treatment of choice before interferon-α
(IFN-α) and deoxycoformycin (DCF) became available in
the 1980s. Treatment with IFN-α results in hematological
responses in 70–90% of patients; however, complete remis-
sions (CRs) are unusual [12–14]. DCF has an overall response
rate of 79–100% in HCL patients, and CRs in the bone marrow
were seen in 56–89% of patients [15–18]. The reluctance of
many investigators to recommend DCF as first-line treatment
for HCL is primarily based on concerns over the toxicity of the
drug [19].
More recently, 2-chlorodeoxyadenosine (cladribine, CDA)
has been introduced as yet another treatment for HCL [20]
resulting in response rates of 90–100%, with 70–90% of
patients achieving a CR as defined by complete disappearance
of hairy cells in the bone marrow [21–24]. The remissions are
usually long-lasting, and the outcome after CDA treatment
seems not to be affected by previous therapies [25, 26]. Not-
ably, CDA therapy is associated with minimal acute and sub-
acute side-effects. Moderate bone marrow depression is the
main toxicity. The granulocyte nadir is usually seen during the
second week after initiation of a 7-day treatment course.
Febrile temperatures occurring early after treatment usually
result from non-infectious reasons such as lysis of hairy cells
with release of pyrogens. Infections during the granulo-
cytopenic period are less common and may be promoted by
concomitant treatment with immunosuppressive agents such
as steroids [23]. As concerns late toxicities, there is evidence
from a number of studies that CDA treatment induces a
marked and long-lasting, yet transient reduction in the number
of normal peripheral blood lymphocytes including T cells,
natural killer (NK) cells and B cells [22, 23]. The clinical
significance of this immunosuppression with regard to the
occurrence of opportunistic infections, the incidence of sec-
ondary neoplasms, and the subsequent course of HCL is still
controversial.
The standard schedule for CDA in most studies was an
intravenous infusion of 0.1 mg/kg/day for 7 days, and remis-
sions were achieved after one single treatment course in the
majority of patients. However, this schedule requires either an
infusion pump or hospitalization of the patients. In addition,
a substantial rate of phlebitis (up to 19%) has been observed in
some series after continuous intravenous CDA infusion for 7
days [27]. CDA has also been administered as a 2-h infusion
for five consecutive days [28]. Still, a more convenient and
cost-saving route of administration is desirable for HCL
patients. We [29] and others [30–32] have shown that subcuta-
neous bolus administration of CDA is tolerated without
complications and with a 100% bioavailability. We therefore
wished to evaluate the clinical activity and toxicity of CDA
given by subcutaneous bolus injections to HCL patients.
Patients and methods
Study design and treatment
In this multicenter phase II study, all patients received a first treatment
cycle with CDA at a dose of 0.14 mg/kg/day by subcutaneous bolus injec-
tion for five consecutive days (total dose 0.7 mg/kg). Patients not respond-
ing to this first cycle subsequently received a maximum of two additional
cycles with CDA given at the same total dose but as a continuous intra-
venous infusion over seven consecutive days. CDA was produced by
Lipomed AG, Basel, Switzerland, and provided in vials containing 10 mg
of the drug in NaCl 0.9% at a concentration of 2 mg/ml.
Patients were advised to maintain a good hydration state during admin-
istration of CDA. Allopurinol was recommended at a dose of 100 mg/day
(300 mg/day in case of elevated serum uric acid) orally for a period of
2 weeks, starting on day 1 of each CDA cycle.
An acute infection had to be controlled by antibiotic treatment before
CDA therapy was started. Patients who developed neutropenia with fever
>38°C following CDA therapy were initially given intravenous anti-
biotics after taking at least three blood cultures. However, the majority of
these patients had sterile blood cultures and no evidence of infection.
Therefore, the approach to neutropenic fever changed during the course of
the study, and febrile patients with sterile blood cultures were given oral
antibiotics for a period depending on the patient’s condition and the level
of suspicion for infection. An infection was assumed if fever >37°C was
accompanied by organ-related symptoms (such as cough or dysuria) or in
the case of documented bacteremia. Administration of hematopoietic
growth factors was allowed in cases of severe documented infection in
neutropenic patients. Other ancillary treatments were given as indicated
clinically. Prophylactic antiemetics were not given routinely. Packed red
blood cells were administered for symptomatic anemia. Prophylactic
platelet transfusions were given if the platelet count was <5 × 109/l in
afebrile patients or <10 × 109/l in febrile patients.
Eligibility and monitoring of patients
Patients of any age with newly diagnosed HCL or progressive disease
(PD) after previous treatment not including CDA (splenectomy, IFN-α,
DCF) were eligible for this study. Eligibility criteria included WHO per-
formance score ≤2, expected survival time >3 months, serum creatinine
<200 µmol/l and bilirubin <35 µmol/l (unless due to HCL), and negative
HIV serology. Patients were not eligible in the case of pregnancy, any
ongoing treatment for HCL (cytotoxic drugs, IFN-α), prior therapy within
4 weeks before start of study treatment, unresolved toxicity from previous
treatment, previous or concurrent additional malignancy other than in situ
carcinoma of the cervix and basal or squamous cell carcinoma of the skin.
All patients gave written informed consent to participate in the study,
which was approved by the local ethical committee of each participating
institution.
In all patients, the diagnosis of classic or variant HCL was established
by morphology including peripheral blood smear and bone marrow exam-
ination (trephine biopsy and, if possible, aspirate). In the majority of
patients, bone marrow slides were also stained for TRAP and reticulin
fibers. Pretreatment evaluation of patients included clinical examination,
complete blood count (including reticulocytes), immunophenotyping of
peripheral blood lymphocytes by flow cytometry (including T cells, T
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helper cells, T suppressor cells, NK cells, normal B cells and hairy cells),
biochemical parameters [including calcium, albumin, creatinine, aspar-
tate aminotransferase, alkaline phosphatase, bilirubin, uric acid, lactate
dehydrogenase (LDH), cholesterol, serum protein electrophoresis], a
chest X-ray and an abdominal computed tomography scan or sonography.
After start of the study treatment, peripheral blood counts, biochemical
parameters, and peripheral blood lymphocyte immunophenotyping (flow
cytometry) were repeated weekly during the first month, at 6 weeks and at
10 weeks after each treatment cycle, then every 3 months for 2 years, and
every 6 months thereafter.
Response and toxicity criteria
Response status (including bone marrow examination and imaging of
other tumor manifestations) was assessed at 4 weeks and at 10 weeks after
treatment start, and every 6 months thereafter, according to the Consensus
Resolution [33] using the following criteria.
A CR was defined as the complete disappearance of all evidence of
disease and required all of the following: normal peripheral blood counts
(hemoglobin >120 g/l, neutrophils >1.5 × 109/l, platelets >100 × 109/l);
absence of hairy cells (by morphological examination) in the peripheral
blood and in the bone marrow, with reversion of TRAP stain to negative
(if positive initially); regression to normal of disease-related organomegaly.
A partial remission (PR) required all of the following: normal periph-
eral blood counts (as in CR); circulating hairy cells ≤5% of lymphocytes;
>50% reduction of bone marrow infiltration by hairy cells; >50% reduc-
tion of palpable disease-related organomegaly.
A minor response (MR) required all of the following: >50% reduction
of circulating hairy cells; improvement of one or more of the peripheral
blood counts (hemoglobin, neutrophils, platelets).
Non-responders were patients not meeting the criteria for CR, PR or MR.
Relapse was defined as the reappearance of hairy cells in the bone
marrow or as any other new disease manifestations in patients with pre-
viously documented CR.
PD was defined as the occurrence of new disease manifestations, as
>50% increase in the percentage of residual tumor cells, or as >50%
increase of residual disease-related organomegaly in patients with previ-
ously documented PR.
Time to treatment failure (TTF) was defined as the time between treat-
ment start and progression, relapse, second tumor, or death, whichever
occurred first. 
Overall survival (OS) was measured from the commencement of treat-
ment until death from any cause.
Early death was defined as death within 4 weeks after administration of
the last CDA dose.
Toxic death was defined as any death to which CDA toxicity may have
contributed.
Hematological and non-hematological side-effects were graded
according to the expanded National Cancer Institute toxicity criteria.
Statistical considerations
The endpoints of the study were: (i) to define the rates of CR and PR, time
to achieve a remission, TTF, and OS in HCL patients treated with CDA by
subcutaneous bolus injections; (ii) to determine the incidence of side-
effects of treatment with CDA; and (iii) to assess by serial immunopheno-
typing the proportion of peripheral blood lymphocyte subpopulations
(T cells, T-cell subsets, NK cells, normal and neoplastic B cells) during
and after CDA treatment, and to investigate the possible clinical signifi-
cance of lymphocyte subpopulation shifts with special regard to the sub-
sequent course of disease and rate of infections.
The sample size of this phase II study was determined as suggested by
Simon [34]. A two-stage design was used, setting the significance level at
5% and the power of the study at 90%. The minimal response rate of inter-
est was defined as 70%. Fifteen patients were necessary in the first stage,
and, if 11 or less were responding, the trial was to be closed. Otherwise, an
additional 21 patients were planned in order to complete the study, for a
total number of 36. The planned sample for the second stage was reached
in August 1994. At that time, considering the high response rate and the
lack of an immediately available better therapeutic option for this group of
patients, it was decided to continue the study. The study was closed in
May 1995, soon before activation of the succeeding study. The increased
sample allows a more precise estimation of the response rate.
Associations were tested with a chi-square or Fisher’s exact test as
appropriate. The correlation between pretreatment values of laboratory
parameters and qualitative parameters was determined using the Wilcoxon
two-sample or the Kruskal–Wallis test as appropriate. Correlation was
determined with Spearman’s rank correlation. Laboratory parameters
were analyzed as both continuous and categorial variables.
Predictive factors for ‘early CR’ (within 10 weeks) and ‘overall CR’
were analyzed with contingency tables and multivariate logistic regres-
sion [35]. Odds ratios [ORs, with 95% confidence intervals (CI) and
P values] were estimated with respect to the reference category for each
covariate using binary variables.
TTF and OS were estimated according to Kaplan and Meier [36] and
compared using the log-rank test [37]. Observations were censored for
patients last known to be without events for TTF or alive for OS. Standard
errors were estimated using Greenwood’s formula. Univariate analysis
was used to assess individual correlations with prognosis (TTF). Multi-
variate analysis using the Cox proportional hazard model was performed
[38]. A likelihood ratio test was used as an indicator of the overall signifi-
cance of a new variable in addition to the model including only clinical
variables [39]. All P values are two-sided. No correction has been per-
formed for multiple evaluations.
Results
Accrual and patients’ characteristics
A total of 63 consecutive patients were registered within 21
months. One registered patient was ineligible because of a
concomitant renal cell cancer. All reported results refer to the
62 eligible patients. The characteristics of these patients are
shown in Table 1. The male:female ratio was 47:15. In two
cases, a prolymphocytic variant was diagnosed, whereas 60
patients had classic HCL. Thirty-three patients had newly
diagnosed HCL, 15 patients had a relapse after previous treat-
ment, and 14 patients had PD during a previous medical treat-
ment other than CDA. No patient had been treated with DCF,
and no patient had been treated with CDA given intravenously
before entering the study. Most patients without previous
splenectomy had an enlarged spleen, and a minority of
patients had hepatomegaly or lymphadenopathy. The median
time from diagnosis was 13 months (range 0–227 months).
Responses
The responses induced by CDA treatment are shown in Table
2. Sixty patients achieved a CR or PR, for an overall remission
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rate of 97%. Forty-seven patients achieved a CR (76%; 95%
CI 63% to 86%), and 13 patients (21%) achieved a PR. A
single patient who received one CDA cycle only did not
achieve a remission. No additional CDA was given to this
patient because of medical problems unrelated to HCL and not
due to toxicity. This patient died 13 months after CDA therapy
from cardiac failure. One patient was not evaluable for
response because treatment with IFN-α was initiated 2 weeks
after CDA therapy.
Two patients were given more than one treatment cycle.
One patient who was in PR after the first course received a sec-
ond cycle and achieved a CR; the second patient who was in
PR after the first course received two additional cycles but
remained in PR.
A summary of the responses at serial evaluations is given in
Table 2. The percentages were calculated including all eligible
patients and therefore slightly underestimate the response rate
in evaluable patients. Most responses occurred early (i.e.
within 10 weeks) after the start of CDA therapy. However, the
response quality kept improving during weeks and even
months after treatment completion, with most complete
responses occurring later than 10 weeks after start of the first
CDA cycle.
The patients’ characteristics listed in Table 1 as well as
baseline hematological parameters (hemoglobin, leukocytes,
granulocytes, lymphocytes, platelets) and biochemical param-
eters (LDH, albumin, cholesterol) were examined for possible
associations with achievement of either early CR (within 10
weeks) or overall CR. Univariate analysis revealed that early
CR was more frequent in patients with normal baseline hemo-
globin (P = 0.05), but there was no other significant associ-
ation with any of the factors examined. Multivariate analysis
confirmed that patients with a normal baseline hemoglobin
had a higher probability to achieve an early CR (OR 3.6, 95%
CI 1.02–12.9, P = 0.047), and among pretreated patients,
females may have a lower probability to achieve overall CR
(OR 9.5, P = 0.06).
Table 1. Characteristics of eligible patients (n = 62)
aPatients may have had more than one previous therapy or organs 
involved.
bWith alkylating agents.
No. Percent
Gender
Male 47 76
Female 15 24
Performance status
0 46 74
1 13 21
2 3 5
Hairy cell leukemia subtype
Classic 60 97
Prolymphocytic 2 3
Status at study entry
Non-pretreated 33 52
First/second/third relapse 15 24
Progressive disease during treatment with
Interferon-α 10 16
Interferon-α and chlorambucil 3 5
Chlorambucil and prednisone 1 2
Previous therapiesa
Splenectomy 10 16
Radiotherapy 0 –
Chemotherapy aloneb 3 5
Interferon-α ± chemotherapy 24 39
Organ involvementa
Splenomegaly 38 61
Hepatomegaly 10 16
Lymphadenopathy 15 24
Other (multiple lung nodules) 1 2
Table 2. Responses
aAll eligible patients included in the percentage calculations.
bOne patient with complete remission at 10 weeks not evaluable at follow-up due to early death.
n.a., not applicable; PD, progressive disease.
Best response at any time Four weeks Ten weeks Any follow-up (>10 weeks)
n % n %a n %a n %a
Complete response 47 76 7 11 11 18 46b 74
Partial response 13 21 41 66 38 61 7 11
Minor response/no response 1 2 8 13 2 3 1 2
PD after previous response n.a. n.a. 0 0 1 2 0 0
Not assessed/not evaluable 1 2 6 10 10 16 8 13
Total 62 100 62 100 62 100 62 100
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Time to treatment failure and overall survival
At a median follow-up of 3.8 years, the following events indi-
cating treatment failure were observed: progression after PR
in seven patients (one of whom died); relapse after CR in eight
patients; second tumors in three patients (two of whom died);
and death from other causes in two patients.
The second malignancies were a brain tumor (glioblastoma
multiforme) detected 2 months after CDA treatment (HCL in
CR) and an adenocarcinoma of the pancreas detected 28 months
after CDA treatment (HCL in CR); these two patients died
from their second tumors. An additional patient developed a
renal cell cancer 5 months after CDA therapy; this patient is
alive and in CR from both HCL and renal cell cancer follow-
ing surgical resection of the second tumor.
One patient with progressive HCL (after PR) died from
a neutropenic infection 22 months after CDA treatment.
Another patient, who had no response to CDA therapy, died
from cardiac failure 13 months after CDA.
The median TTF for all patients was 38 months (Figure 1).
The failure-free proportion is 0.90 [standard error (SE): 0.04]
at 1 year and 0.76 (SE: 0.05) at 2 years, respectively. Using
univariate analysis, TTF was shorter for patients without sys-
temic pretreatment as compared with patients in relapse or
with progression after systemic pretreatment (failure-free pro-
portion at 2 years 0.68 versus 0.83, P = 0.04). Patients with
hepatomegaly had a significantly shorter TTF as compared
with patients with normal liver size (failure-free proportion at
2 years 0.60 versus 0.79, P = 0.03). Shorter TTF was also
observed in patients with decreased baseline hemoglobin
(failure-free proportion at 2 years 0.69 versus 0.87, P = 0.06)
and platelets (failure-free proportion at 2 years 0.70 versus
0.93, P = 0.04).
By multivariate analysis, the OR for failure was 2.46 (95%
CI 0.88–6.84, P = 0.09) for patients without systemic pretreat-
ment in a model adjusted for hepatic involvement and baseline
platelet count. Pretreatment was considered for subgroup
analysis. In non-pretreated patients, the estimated OR for
hepatic involvement was 3.1 (95% CI 0.97–9.8, P = 0.055) in
a model adjusted for baseline hemoglobin. Interpretation of
these results should be cautious since the subgroups contain
few patients, and few failures were observed.
The median OS has not been reached so far. The proportion
alive is 0.97 (SE: 0.02) at 1 year and 0.93 (SE: 0.03) at 2 years.
Toxicities
All but one patient were evaluable for hematological toxicity.
Pretreatment and nadir values of hematological parameters
are given in Table 3. CDA treatment induced considerably low
leukocyte nadirs. Granulocyte nadir was less than 50% of the
pretreatment value in 73% of patients, and lymphocyte nadir
was less than 50% of the pretreatment value in 88% of
patients. Serial assessment of peripheral blood lymphocytes
and lymphocyte subpopulations including T cells, T-cell sub-
sets, non-malignant B cells and NK cells revealed a marked
Figure 1. Time to treatment failure (with 95% confidence intervals).
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but non-specific lymphopenia with rapid onset after treatment
with CDA (see Figure 2). Nadir values were recorded 1 week
after treatment start for all subpopulations except for B cells
(nadir after 2 weeks). All subpopulations subsequently recov-
ered, but recovery was generally slow and required several
months. In one patient with excessive (>95%) bone marrow
infiltration by hairy cells and agranulocytosis at study entry,
granulocyte recovery required 9 months, whereas normal
granulocyte counts were reached within some weeks in all
other patients.
In contrast to white blood cells, toxicity was less severe for
hemoglobin and platelets. In 67% of patients, hemoglobin
nadirs were higher than 75% of pretreatment values, and, of
particular interest, no decrease in platelet counts was observed
in 36% of patients.
A total of 50 infectious episodes were seen in 35 patients at
any time after CDA. Early infections (≤10 weeks after CDA
treatment) were observed in 36 cases (26 infections within 4
weeks and 10 infections between 4 and 10 weeks after CDA
treatment), and late infections (>10 weeks after CDA treat-
ment) in 14 instances. Most infections were mild, but nine
were graded as moderate (grade II) and 12 as severe (grade
≥III, requiring oral or intravenous antibiotics). While the
infectious agent was not identified in most cases, herpes sim-
plex virus was found in three patients, E. coli in one patient,
and S. pneumoniae in one patient. No opportunistic germs
were identified. One patient with progressive HCL (after pre-
vious PR) and neutropenia died from pneumonia 22 months
after CDA treatment. All other infections resolved after appro-
priate treatment. No association was found between infections
and nadir counts of lymphocytes or lymphocyte subpopula-
tions. However, infections were strongly associated with nadir
granulocyte count (P = 0.0013).
Other severe (grade ≥III) clinical toxicities included a gastro-
intestinal hemorrhage (in a patient with preexisting peptic
ulcer), a cardiac failure (in a patient with preexisting coronary
heart disease) and a mental depression in one patient each, and
CDA treatment was probably not a major underlying factor
in these events. As mentioned earlier, second tumors were
Table 3. Baseline and nadir values of hematological parameters
Baseline values Nadir values
Median Range Median Range
Hemoglobin (g/dl) 10.6 4.5–16.3 8.1 4.1–14
Leukocytes (× 109/l) 2.4 0.2–41.1 0.5 0.02–2.1
Granulocytes (× 109/l) 0.7 0.02–2.3 0.2 0–1.6
Lymphocytes (× 109/l) 1.3 0.1–13.9 0.2 0–1.2
Platelets (× 109/l) 64 43–318 52 17–236
Figure 2. Medians of lymphocytes and lymphocyte subpopulations before and after cladribine therapy. NK, natural killer cells.
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diagnosed in three patients. Mild (grade I or II) side-effects
included hemorrhages, high temperature without evidence of
infection, cutaneous rashes, diarrhea, symptoms of anemia,
nausea, edema, bone pain and headache. No patient had
mucositis, vomiting, neurological symptoms or alopecia.
Discussion
Our data confirm the excellent activity of CDA in HCL. In our
series, the overall remission rate was 97%, and 76% of the
patients achieved a CR, defined according to the very stringent
Consensus Resolution criteria. Juliusson et al. [40] reported a
similar CR rate of 75% in their study with subcutaneous CDA
for HCL. Remarkably, our results were obtained with a single
treatment cycle in 60 patients, and only two patients required
more than one cycle. The response quality improved over
weeks and even months after application of a single treatment
cycle without further therapy, as suggested before by limited
data from other investigators [23, 25]. Clearance of hairy cells
from the peripheral blood was seen a few days after treatment
start, whereas clearance from bone marrow was slower, and
normalization of organomegaly (spleen, lymphadenopathy)
usually required 3–6 months. Therefore, observation is justi-
fied in most patients after a single treatment course, unless a
rapid treatment effect is required by clinical features such as
massive organomegaly or severe cytopenia.
We found that rapid achievement of a CR (i.e. within 10
weeks after treatment) was favored by a normal pretreatment
hemoglobin. In agreement with other reports, no other clinical
features predicted the quality of response. The present study
demonstrates that CDA given by subcutaneous bolus injec-
tions may have a clinical efficacy equivalent to the continuous
intravenous application of the same dose. In trials using the
intravenous schedule, CR rates ranged from 50% to 91%,
depending on the methods used to assess the remission status
[22, 41–44].
The median TTF of our cohort was 38 months, with 90%
of patients failure-free at 12 months and 76% at 24 months.
Seventy-five percent of treatment failures were due to relapses
after CR or tumor progression after PR. Few data on TTF only
are available for comparison from other studies in which regu-
lar follow-up bone marrow samples were obtained. Juliusson
et al. [40] reported a progression-free proportion of 68% at 18
months after subcutaneous CDA, but no statements were
made concerning treatment failures other than HCL progres-
sion. In a series using intravenous therapy, failure-free sur-
vival was 93% at 24 months and 81% at 48 months [43]. In
other studies with intravenous therapy, progression-free sur-
vival was 77% at 36 months [45], 72% at 48 months [41], and
80% at 55 months [42]. The differences may be explained by
variable follow-up schedules and methods, since in contrast to
our study no regular bone marrow samples were taken during
follow-up, and less strict response criteria have been applied
in most series.
We observed that TTF was adversely correlated with hepatic
involvement (P = 0.03), while a trend to longer TTF was
observed in patients with normal pretreatment hemoglobin,
normal platelet count and pretreated patients. The latter group
may represent a population with less aggressive disease and
therefore better prognosis. However, these results require
cautious interpretation because subgroups contained few
patients only. In the large Scripps Clinic series, an increased
pretreatment peripheral leukocyte count (>15 × 109/l) and
the presence of a splenomegaly were significant predictors of
TTF [43]. In contrast to a previous report with a small patient
number [46], abdominal lymphadenopathy was not associated
with a shorter TTF in our series.
A pronounced depression of peripheral leukocytes was the
main toxicity of CDA. We found a median granulocyte nadir
of 0.2 × 109/l, and the granulocyte nadir was <25% of the pre-
treatment count in 45% of patients. CDA is also known to
induce profound lymphopenia, and we could demonstrate that
this lymphopenia is non-specific, with all subpopulations
being affected. The median lymphocyte nadir of 0.2 × 109/l
occurred 1 week after the start of CDA treatment. Suppression
of lymphocyte subpopulations was long-lasting, and recovery
took months or even years. In keeping with other studies
[47, 48], NK cells were the fastest to recover, whereas recov-
ery of non-malignant B cells was slower. T-cell recovery was
very prolonged, and all T-cell subpopulations did not reach
normal levels within the observation period of nearly 2 years.
Infections occurred in a significant proportion of patients
predominantly during the first weeks after CDA therapy. The
incidence of infections was strongly associated with granulo-
cyte nadir (P = 0.0013), but no correlations were found
between infections and nadir counts of lymphocytes or any
lymphocyte subpopulation. Moreover, we did not observe
any opportunistic infections. It appears therefore that the long-
lasting immunosuppression resulting from CDA-induced
lymphopenia has no clinical consequences. This is in accord
with other reasonably large studies in which the rate of oppor-
tunistic infections was also low despite a prolonged sup-
pression of CD4+ T cells [22, 41, 42, 45]. We conclude that
neutropenia but not lymphopenia is predictive for infections in
HCL patients receiving one CDA treatment course. This may
be different in patients with other lymphoproliferative dis-
eases who are sometimes heavily pretreated or receive several
treatment courses with CDA.
Second malignancies were detected in three patients. Two
of these malignancies seem not to be related to CDA therapy
since they were detected at 2 and 5 months after CDA treat-
ment. In addition, a pancreatic adenocarcinoma was detected
in one patient 28 months after CDA therapy. An increased
incidence of second malignancies, particularly lymphoid neo-
plasms, in HCL patients is well known [49, 50] and seems to
be due to an intrinsic susceptibility of HCL patients to second
tumors rather than to CDA treatment or CDA-induced immuno-
suppression [42, 45, 49–51]. A particularly high incidence of
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second neoplasms has been reported after treatment with
IFN-α [52].
Data from numerous studies suggest that CDA is the treat-
ment of choice for HCL. In most studies, the drug has been
given intravenously. Oral administration is also possible, but
the bioavailability of oral CDA may considerably vary
between individual patients depending on food intake and
stomach acid [30, 53], and this administration route has not
been pursued by clinical investigators during recent years. The
present study shows that subcutaneous bolus administration of
CDA is very effective. Most patients may find the subcutane-
ous administration more convenient than intravenous infu-
sions, since it allows self-administration of the drug and
infusion devices can be avoided. The subcutaneous adminis-
tration should be offered to every patient with HCL (or any
other lymphoproliferative disorder) requiring treatment with
CDA. At present we are performing a subsequent study in
which CDA is given to HCL patients by weekly subcutaneous
bolus injections.
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